Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity ...

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer's and other neurodegenerative diseases ...